117 related articles for article (PubMed ID: 37898250)
1. An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia.
Mohamed SMA; Schofield P; McCalmont H; Moles E; Friedrich KH; Kavallaris M; Christ D; Bayat N; Lock RB
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127596. PubMed ID: 37898250
[TBL] [Abstract][Full Text] [Related]
2. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
[TBL] [Abstract][Full Text] [Related]
3. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
[TBL] [Abstract][Full Text] [Related]
4. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
5. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
6. Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients.
Gupta DG; Varma N; Kumar A; Naseem S; Sachdeva MUS; Sreedharanunni S; Binota J; Bose P; Khadwal A; Malhotra P; Varma S
Cancer; 2023 Apr; 129(8):1217-1226. PubMed ID: 36738086
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of
Wang J; Sun K; Chen WM; Wang X; Li LD; Hao Y; Xu N; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Jiang Q; Qin YZ
Leuk Lymphoma; 2023 Mar; 64(3):698-706. PubMed ID: 36642937
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
10. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients.
Martínez-Anaya D; Moreno-Lorenzana D; Reyes-León A; Juárez-Figueroa U; Dean M; Aguilar-Hernández MM; Rivera-Sánchez N; García-Islas J; Vieyra-Fuentes V; Zapata-Tarrés M; Juárez-Villegas L; Paredes-Aguilera R; Vega-Vega L; Rivera-Luna R; Juárez-Velázquez MDR; Pérez-Vera P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076986
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
13. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
[TBL] [Abstract][Full Text] [Related]
14. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
[TBL] [Abstract][Full Text] [Related]
15. High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.
Juárez-Velázquez MDR; Moreno-Lorenzana DL; Martínez Anaya DA; Hernández Monterde EA; Aguilar-Hernández MM; Reyes-León A; Chávez-González MA; López Santiago N; Zapata Tarrés M; Juárez Villegas L; Rivera Sánchez N; Soto Lerma O; Vega-Vega L; Rivera Luna R; Pérez-Vera P
Cytokine; 2022 Jul; 155():155896. PubMed ID: 35537330
[TBL] [Abstract][Full Text] [Related]
16. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.
Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA
Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
19. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
